MK-677 (Ibutamoren): The Complete Guide

Overview

MK-677, also known as ibutamoren or ibutamoren mesylate, is an orally active non-peptidyl agonist of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a). It stimulates the release of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) from the pituitary gland by mimicking the action of ghrelin — the endogenous "hunger hormone" (Patchett et al., 1995).

Despite being frequently discussed alongside peptides such as CJC-1295, GHRP-6, and ipamorelin, MK-677 is not a peptide. It is a small molecule — a spiropiperidine compound — that can be taken orally and absorbed through the gastrointestinal tract without degradation. This distinguishes it from peptide-based GH secretagogues, which require injection due to their susceptibility to enzymatic breakdown in the gut.

MK-677 was originally developed by Merck Research Laboratories in the 1990s and advanced through Phase 2 clinical trials for multiple indications, including growth hormone deficiency in the elderly, muscle wasting, osteoporosis, and obesity. While these trials demonstrated consistent GH and IGF-1 elevation and showed effects on body composition and bone density, the compound was never submitted for FDA approval and development was ultimately discontinued (Nass et al., 2008).

The compound has a long plasma half-life of approximately 24 hours, allowing once-daily oral dosing. It produces sustained increases in GH pulsatility and IGF-1 levels without significantly affecting cortisol, prolactin, or thyroid hormone levels at standard doses — a profile that distinguishes it from exogenous GH administration (Patchett et al., 1995).

MK-677 is not FDA-approved for any indication. It is available through research chemical suppliers and is classified as a prohibited substance by WADA. Because it is a small molecule rather than a peptide, it is not subject to the FDA's peptide compounding category system.

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

Ghrelin Receptor Agonism

MK-677 acts as a functional mimetic of ghrelin, the endogenous ligand of the growth hormone secretagogue receptor (GHS-R1a). Ghrelin is a 28-amino-acid peptide hormone produced primarily in the stomach that stimulates appetite and GH release. MK-677 binds to the same receptor but is structurally unrelated to ghrelin — it is a synthetic small molecule designed to reproduce ghrelin's GH-releasing effects orally (Patchett et al., 1995).

When MK-677 binds GHS-R1a in the hypothalamus and anterior pituitary, it triggers a signaling cascade that results in the release of growth hormone-releasing hormone (GHRH) and direct stimulation of somatotroph cells to secrete GH. This occurs in a pulsatile pattern that mimics physiological GH secretion — unlike exogenous GH injection, which produces a non-physiological spike and suppresses endogenous production (Patchett et al., 1995).

GH and IGF-1 Elevation

Clinical studies have demonstrated that MK-677 at 25 mg daily produces:

• GH increase: Approximately 97% increase in peak GH levels and significant increases in 24-hour GH area-under-curve (AUC) in healthy elderly subjects (Nass et al., 2008)
• IGF-1 increase: Sustained elevation of IGF-1 levels by approximately 40–60%, bringing elderly subjects' IGF-1 into the range of healthy young adults (Nass et al., 2008)
• Maintained pulsatility: GH continues to be released in pulses rather than a constant elevation, preserving the physiological secretion pattern (Patchett et al., 1995)

These increases are sustained over long-term use. A 2-year study in elderly subjects showed that IGF-1 elevation was maintained throughout the study period without tachyphylaxis (loss of effect), though GH levels showed some attenuation after the first year (Nass et al., 2008).

Selectivity: What It Does NOT Affect

An important pharmacological feature of MK-677 is its relative selectivity. At standard doses (25 mg/day), clinical studies have shown:

• Cortisol: No significant sustained increase in cortisol levels. Transient cortisol elevations may occur acutely but do not persist with continued dosing (Patchett et al., 1995)
• Prolactin: No clinically significant changes (Nass et al., 2008)
• Thyroid hormones (T3, T4, TSH): No significant changes (Nass et al., 2008)
• Testosterone/LH/FSH: No direct effects on gonadal axis (Patchett et al., 1995)

This selectivity profile is a key distinction from exogenous GH administration, which can affect multiple endocrine axes and suppress endogenous GH production via negative feedback.

Appetite Stimulation

Because ghrelin is the primary appetite-stimulating hormone, MK-677's agonism of the ghrelin receptor produces significant appetite increases in most users. This is a direct pharmacological effect, not a side effect — it is an inherent consequence of ghrelin receptor activation. The appetite stimulation is most pronounced during the first weeks of use and may attenuate partially over time (Chapman et al., 1996).

Effects on Sleep Architecture

MK-677 has been shown to improve sleep quality in clinical studies. A study in young healthy subjects demonstrated that MK-677 increased Stage IV (deep) sleep duration by approximately 50% and increased REM sleep duration by approximately 20%. These effects are mediated through GH's known role in sleep regulation and potentially through direct ghrelin receptor effects on sleep centers (Copinschi et al., 1997).

Insulin and Glucose Effects

MK-677 increases fasting blood glucose and fasting insulin levels. This is consistent with GH's known counter-regulatory effects on glucose metabolism. In the 2-year Nass et al. study, fasting glucose increased by approximately 0.3 mmol/L and fasting insulin increased significantly, with some subjects developing impaired glucose tolerance (Nass et al., 2008). This insulin resistance effect is a significant clinical consideration and is discussed further in the Side Effects tab.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

2-Year Trial in Healthy Elderly Adults

The most comprehensive MK-677 study is a 2-year, double-blind, placebo-controlled trial conducted by Nass et al. in 65 healthy elderly adults (60–81 years). Subjects received 25 mg MK-677 or placebo daily. Key findings:

• GH and IGF-1: MK-677 increased GH and IGF-1 to levels comparable with healthy young adults. IGF-1 elevation was sustained throughout the 2-year study period (Nass et al., 2008).
• Body composition: Fat-free mass (lean mass) increased significantly in the MK-677 group compared to placebo. Fat mass did not change significantly, though body weight increased due to lean mass gains and water retention (Nass et al., 2008).
• Insulin resistance: Fasting glucose increased by ~0.3 mmol/L. Fasting insulin increased significantly. Some subjects developed impaired fasting glucose. The investigators noted this as a significant safety concern (Nass et al., 2008).
• Tolerability: The most common side effects were increased appetite, transient edema (swelling), and muscle pain. Dropout rates were comparable between groups (Nass et al., 2008).

Body Composition in Obese Males

A study by Svensson et al. examined MK-677 at 25 mg daily for 8 weeks in obese males. Results showed:

• Significant increase in GH secretion and IGF-1 levels
• Increase in fat-free mass by approximately 3 kg
• No significant change in visceral fat
• Increase in fasting glucose and insulin, consistent with other MK-677 trials

(Svensson et al., 1998)

GH-Deficient Adults

Chapman et al. studied MK-677 in adults with relative GH deficiency (low IGF-1). Daily oral administration of 25 mg for up to 12 months produced:

• Sustained increases in GH pulsatile secretion
• IGF-1 levels normalized to the range of healthy young adults
• Increases in fat-free mass
• The GH response was maintained without evidence of tachyphylaxis at 12 months

(Chapman et al., 1996)

Bone Density

Multiple studies have evaluated MK-677's effects on bone metabolism:

• Postmenopausal women: Murphy et al. studied MK-677 at 25 mg daily for 18 months in postmenopausal women. The treatment increased bone mineral density (BMD) at the femoral neck and showed increased markers of bone turnover (osteocalcin, bone-specific alkaline phosphatase), suggesting enhanced bone formation (Murphy et al., 2001).
• Elderly subjects: In the 2-year Nass et al. trial, bone turnover markers increased in the MK-677 group, consistent with increased bone remodeling driven by GH/IGF-1 elevation (Nass et al., 2008).

Sleep Quality

Copinschi et al. studied the effects of MK-677 on sleep architecture in healthy young men using polysomnography. Key findings:

• Stage IV (deep/slow-wave) sleep duration increased by approximately 50%
• REM sleep duration increased by approximately 20%
• Sleep efficiency improved overall
• These effects are consistent with the known role of GH in sleep regulation

(Copinschi et al., 1997)

Catabolic States

MK-677 has been studied for its potential to reverse catabolic states:

• Diet-induced catabolism: Murphy et al. demonstrated that MK-677 reversed diet-induced nitrogen wasting (protein loss) in healthy volunteers subjected to caloric restriction, suggesting potential for preserving muscle mass during caloric deficit (Murphy et al., 1998).
• Hip fracture recovery: A trial in elderly patients recovering from hip fracture showed improved functional outcomes in the MK-677 group, though the study was limited by small sample size (Murphy et al., 2001).

Limitations of the Research

• No Phase 3 trials: Despite promising Phase 2 data, MK-677 was never advanced to Phase 3 registration trials. Merck discontinued development, likely due to the insulin resistance concerns and uncertain regulatory path.
• Moderate sample sizes: The largest trial (Nass et al.) enrolled 65 subjects. Most other trials enrolled 20–40 subjects.
• Insulin resistance: Every major MK-677 trial has documented increases in fasting glucose and insulin. This consistent finding likely contributed to the decision not to pursue FDA approval.
• Limited disease-specific outcomes: While GH/IGF-1 elevation and body composition changes have been consistently demonstrated, clinically meaningful disease outcomes (fracture prevention, functional improvement, mortality benefit) have not been established.
• Single-sponsor research: Most clinical trials were sponsored by Merck. Independent replication of clinical outcomes has been limited.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA Status

MK-677 has no FDA-approved indication. It is not classified as a drug, dietary supplement, or approved pharmaceutical by the FDA. Clinical development was discontinued after Phase 2 trials. Any use is considered experimental.

Important Classification Note

MK-677 is not a peptide — it is a small molecule (spiropiperidine derivative). This distinction matters for regulatory purposes: it is not subject to the FDA's peptide compounding category system (Category 1/2/3) that governs compounds like BPC-157 and thymosin alpha-1. It is also not available through compounding pharmacies under peptide compounding frameworks. It is obtained primarily through research chemical suppliers.

Investigated and Reported Applications

What MK-677 Is NOT Used For

• Fat loss: Despite GH's lipolytic effects, MK-677 does not reliably reduce fat mass in clinical trials. The appetite-stimulating effects may counteract any fat-loss benefit in practice.
• Diabetes or metabolic improvement: MK-677 worsens insulin sensitivity. It should not be used with the expectation of metabolic benefit.
• Direct muscle building: MK-677 increases lean mass through GH/IGF-1 elevation and water retention, but it is not an anabolic steroid and does not directly stimulate muscle protein synthesis at the same magnitude.
• Growth in children/adolescents: MK-677 has not been studied in pediatric populations and should not be used in individuals whose growth plates have not closed.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

Doses Used in Clinical Trials

Sources: Nass et al. (2008) — 25 mg dosing over 2 years, Annals of Internal Medicine; Chapman et al. (1996) — daily oral dosing protocol, JCEM; Svensson et al. (1998) — 25 mg for 8 weeks in obese males, JCEM.

Administration Timing

MK-677 is commonly taken at bedtime for two reasons:

• GH physiology: The largest natural GH pulse occurs during early sleep. Taking MK-677 at bedtime amplifies this physiological surge, potentially maximizing the GH response (Copinschi et al., 1997).
• Appetite management: Because MK-677 significantly increases appetite within 1–2 hours of dosing, bedtime administration allows users to sleep through the peak appetite effect.
• Sleep benefit: The sleep-enhancing effects (increased deep sleep and REM) are experienced when taken before bed.

Cycling Patterns

There is no established evidence base for optimal cycling. Approaches reported in practice include:

• Continuous use: The 2-year Nass et al. trial used continuous daily dosing without breaks. IGF-1 elevation was maintained throughout.
• 8–12 week cycles: Some users cycle MK-677 for 8–12 weeks followed by 4–8 weeks off, primarily to manage insulin sensitivity.
• 5 days on, 2 days off: An unvalidated approach aimed at maintaining GH/IGF-1 benefits while providing periodic breaks from ghrelin receptor stimulation.

The decision to cycle or use continuously should be informed by blood glucose and insulin monitoring, as insulin resistance is cumulative with duration of use.

Monitoring Recommendations

Given MK-677's effects on glucose metabolism, the following monitoring is commonly recommended in clinical practice:

• Fasting blood glucose: Baseline and every 4–8 weeks during use
• Fasting insulin: Baseline and periodically
• HbA1c: Baseline and every 3 months for long-term use
• IGF-1 levels: To confirm response and avoid supraphysiological elevation
• Lipid panel: Baseline and periodically, as GH affects lipid metabolism

Storage

• Capsules: Store at room temperature in a dry location, away from light and moisture.
• Liquid solutions: Refrigerate after opening. Use within the timeframe specified by the supplier.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What to Expect

Timeline of Effects

What Clinical Trials Measured

• Fat-free mass increase: Approximately 2–3 kg over 8–12 weeks at 25 mg daily (Svensson et al., 1998)
• IGF-1 increase: 40–60% sustained elevation, restoring elderly subjects to young-adult ranges (Nass et al., 2008)
• Deep sleep increase: ~50% increase in Stage IV sleep duration (Copinschi et al., 1997)
• Bone density: Increased femoral neck BMD in postmenopausal women at 18 months (Murphy et al., 2001)
• Nitrogen balance: Reversal of diet-induced catabolism within 7 days (Murphy et al., 1998)

Important Caveats

• Weight gain includes water: Initial weight increases (first 2–4 weeks) are substantially water retention, not pure muscle growth. This is a GH-class effect and resolves upon discontinuation.
• Not a substitute for training: Lean mass gains from MK-677 alone are modest. The compound does not replace resistance training or adequate protein intake for meaningful muscle development.
• Individual variation: GH response varies significantly between individuals based on age, baseline GH status, body composition, genetics, and sleep quality.
• Diminishing GH response: While IGF-1 elevation is sustained long-term, direct GH elevation may attenuate after 6–12 months of continuous use (Nass et al., 2008).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Documented Side Effects from Clinical Trials

Insulin Resistance: The Primary Safety Concern

The insulin resistance caused by MK-677 warrants special attention. This is not a rare side effect — it is a consistent, dose-related pharmacological consequence of sustained GH elevation:

• Mechanism: GH is a counter-regulatory hormone to insulin. Sustained GH elevation increases hepatic glucose output and reduces peripheral glucose uptake, leading to higher fasting glucose and compensatory hyperinsulinemia (Nass et al., 2008).
• Clinical trial data: In the 2-year Nass et al. study, fasting glucose increased by approximately 0.3 mmol/L (5.4 mg/dL) and fasting insulin increased significantly in the MK-677 group. Some subjects met criteria for impaired fasting glucose.
• Cumulative with duration: Insulin resistance effects tend to increase with duration of use rather than attenuate.
• Higher risk populations: Individuals who are already insulin-resistant, prediabetic, diabetic, or obese are at higher risk for clinically significant glucose impairment.
• Monitoring essential: Regular fasting glucose, fasting insulin, and HbA1c monitoring is recommended for anyone using MK-677.

Contraindications

• Diabetes mellitus (Type 1 or Type 2) — MK-677 worsens insulin sensitivity and may impair glycemic control
• Active cancer or recent cancer history — GH and IGF-1 elevation may promote tumor growth in hormone-sensitive cancers
• Pregnancy and breastfeeding — no safety data available
• Children and adolescents — no pediatric data; potential effects on growth plate closure unknown
• Congestive heart failure — fluid retention may worsen symptoms
• Pituitary tumors — GH-secreting adenomas may be stimulated

Drug Interactions

No formal drug interaction studies have been published. Theoretical interactions include:

• Diabetes medications (metformin, insulin, sulfonylureas): MK-677 opposes their glucose-lowering effects. Dose adjustments may be needed.
• Corticosteroids: Additive insulin resistance and fluid retention.
• Diuretics: May partially counteract MK-677-induced edema, but electrolyte monitoring becomes important.
• Other GH secretagogues or exogenous GH: Additive GH/IGF-1 elevation with potentially compounded side effects.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA Status

MK-677 was developed by Merck Research Laboratories and advanced through Phase 2 clinical trials but was never submitted for FDA approval. It remains an unapproved investigational compound. Key regulatory distinctions:

• Not a controlled substance: MK-677 is not scheduled under the Controlled Substances Act. Possession for personal use is not a federal crime in the United States.
• Not a peptide: MK-677 is a small molecule (spiropiperidine). It is not subject to the FDA's bulk drug substance category system for peptides (Category 1/2/3) that governs compounds like BPC-157, thymosin alpha-1, and other peptide therapies.
• Not a dietary supplement: MK-677 does not meet the definition of a dietary supplement under DSHEA. Products marketed as supplements containing MK-677 are in violation of FDA regulations.
• Research chemical status: MK-677 is legally sold as a research chemical with "not for human consumption" labeling. This places it in a regulatory gray area — the compound itself is not illegal to sell or possess, but marketing it for human use without FDA approval is prohibited.

WADA Prohibited Status

The World Anti-Doping Agency (WADA) lists MK-677 as a prohibited substance under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), specifically as a growth hormone secretagogue. This means:

• Prohibited at all times (in-competition and out-of-competition)
• No Therapeutic Use Exemption (TUE) framework exists since MK-677 has no approved therapeutic indication
• Validated detection methods exist for MK-677 in urine and blood
• Athletes subject to WADA testing face standard anti-doping sanctions for positive results

International Regulatory Status

Comparison with Peptide GH Secretagogues

MK-677's regulatory position differs from peptide-based GH secretagogues (e.g., CJC-1295, ipamorelin, GHRP-2/6, sermorelin) in important ways:

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Pricing

Insurance Coverage

MK-677 is not covered by any insurance plan. It has no FDA-approved indication and cannot be billed under any drug benefit, medical benefit, or prescription plan. All costs are out-of-pocket.

Cost Comparison: GH Secretagogues and GH Therapy

Factors Affecting Cost

• Dose: 10 mg daily costs roughly half as much as 25 mg daily. Many users start at 10 mg to assess tolerance before increasing.
• Supplier reputation: Suppliers with third-party testing and established reputations tend to charge more than unverified sources.
• Form: Capsules cost more than liquid, which costs more than raw powder, reflecting the additional processing involved.
• No injection supplies needed: Unlike peptide GH secretagogues, MK-677 requires no syringes, bacteriostatic water, or alcohol swabs — eliminating $20–$40/month in supply costs.
• No provider visits required for administration: Oral dosing does not require injection training or provider oversight for administration technique (though medical supervision for monitoring remains important).

Total Cost of Use

When considering total cost, factor in monitoring bloodwork:

• Baseline labs (fasting glucose, insulin, IGF-1, lipids, HbA1c): $100–$300 (or covered by insurance if ordered by a provider for general metabolic screening)
• Follow-up labs every 2–3 months: $50–$200 per panel
• Provider consultation (if applicable): $100–$300 for initial visit

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Myth: MK-677 is a SARM.

Answer: MK-677 is not a selective androgen receptor modulator (SARM). It does not bind to or modulate the androgen receptor in any way. It is a ghrelin receptor agonist — a completely different mechanism. The confusion arises because MK-677 is frequently sold alongside SARMs by research chemical suppliers and discussed on the same forums. Structurally and pharmacologically, it has nothing in common with SARMs like ostarine, LGD-4033, or RAD-140 (Patchett et al., 1995).

Myth: MK-677 is a peptide.

Answer: MK-677 is a small molecule (spiropiperidine derivative), not a peptide. Peptides are chains of amino acids; MK-677 is a synthetic organic compound. This distinction is clinically and regulatorily significant: MK-677 can be taken orally because it survives gastric acid digestion, while peptide GH secretagogues (GHRP-6, ipamorelin, CJC-1295) require injection. It is also not subject to the FDA's peptide compounding category system (Patchett et al., 1995).

Myth: MK-677 is a powerful muscle builder.

Answer: MK-677 increases fat-free mass (lean mass) by approximately 2–3 kg over 8–12 weeks in clinical trials (Svensson et al., 1998). However, a significant portion of this "lean mass" increase includes water retention from GH-induced sodium and fluid shifts — not purely skeletal muscle. MK-677 is not an anabolic steroid and does not stimulate muscle protein synthesis with the same magnitude. It may support modest muscle growth through GH/IGF-1 elevation, particularly when combined with resistance training, but expectations should be calibrated accordingly.

Myth: MK-677 burns fat.

Answer: Despite GH's known lipolytic (fat-burning) properties, clinical trials of MK-677 have not demonstrated significant fat loss. The appetite-stimulating effect of ghrelin receptor agonism tends to increase caloric intake, which may offset any lipolytic benefit. In the Svensson et al. study, fat mass did not change significantly despite increased GH (Svensson et al., 1998). Users expecting fat loss from MK-677 alone are likely to be disappointed.

Myth: MK-677 has no side effects.

Answer: MK-677 has well-documented side effects from multiple clinical trials. The most significant is insulin resistance — every major trial has documented increased fasting glucose and insulin (Nass et al., 2008). Other documented effects include increased appetite, water retention, lethargy, numbness/tingling, and muscle/joint pain. Characterizing MK-677 as side-effect-free is inaccurate and potentially harmful, particularly for individuals with existing metabolic conditions.

Myth: You need to cycle MK-677 to avoid GH suppression.

Answer: MK-677 does not suppress endogenous GH production through negative feedback in the way that exogenous GH injection does. It works by stimulating the body's own GH release mechanism. The 2-year Nass et al. trial demonstrated sustained IGF-1 elevation without evidence of pituitary suppression (Nass et al., 2008). Some GH attenuation was noted after the first year, but this likely reflects receptor desensitization rather than pituitary suppression. Cycling may still be advisable — but for managing insulin resistance, not to prevent GH axis suppression.

Myth: MK-677 is just as good as HGH injections.

Answer: MK-677 and exogenous GH (somatropin) are fundamentally different approaches. Exogenous GH provides supraphysiological, non-pulsatile GH levels and directly suppresses endogenous production. MK-677 stimulates endogenous pulsatile GH release. The GH levels achieved with MK-677 are generally lower than those achieved with therapeutic GH doses, and the clinical effects are correspondingly more modest. MK-677 may be sufficient for individuals with age-related GH decline seeking modest improvements, but it does not replicate the effects of full-dose GH replacement therapy.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• MK-677 (ibutamoren) is an orally active, non-peptidyl ghrelin receptor agonist that increases GH and IGF-1 levels by mimicking ghrelin's action at the pituitary. It is a small molecule — not a peptide, not a SARM, and not an anabolic steroid.
• The human evidence base is stronger than most compounds in this category. Multiple Phase 2 clinical trials have been completed, including a 2-year study in elderly subjects. Data on GH/IGF-1 elevation, body composition, bone density, and sleep quality is available from controlled trials.
• It is not FDA-approved for any indication. Clinical development was discontinued after Phase 2, likely due to insulin resistance concerns. No Phase 3 trials have been conducted.
• Insulin resistance is the primary safety concern. Every major clinical trial has documented increased fasting glucose and insulin. This effect is cumulative with duration of use. Individuals with diabetes, prediabetes, or metabolic syndrome face higher risk. Blood glucose monitoring is essential.
• Documented benefits include: sustained GH/IGF-1 elevation, increased fat-free mass (~2–3 kg), improved sleep quality (deeper sleep, more REM), increased bone turnover markers, and preservation of lean mass during caloric deficit.
• Common side effects include: increased appetite, water retention/edema, lethargy, numbness/tingling, and muscle or joint pain — in addition to the insulin resistance noted above.
• Cost is relatively low ($50–$150/month) compared to other GH secretagogues, and oral administration eliminates the need for injection supplies. It is not covered by insurance.
• It is available through research chemical suppliers and is not subject to the FDA's peptide compounding category system. Product quality varies between suppliers.

Who Might Consider MK-677

Based on the available evidence and clinical trial populations, MK-677 may warrant discussion with a healthcare provider for individuals who:

• Have age-related GH decline with documented low IGF-1 levels
• Seek modest improvements in body composition, sleep quality, or bone density
• Prefer oral administration over injectable GH secretagogues
• Have normal glucose tolerance and can commit to regular metabolic monitoring
• Understand that the evidence, while stronger than for many research compounds, falls short of FDA approval standards

Who Should Avoid MK-677

• Individuals with diabetes, prediabetes, or insulin resistance
• Individuals with active or recent cancer (GH/IGF-1 may promote tumor growth)
• Individuals with congestive heart failure (fluid retention risk)
• Athletes subject to WADA or other anti-doping testing
• Pregnant or breastfeeding individuals
• Children and adolescents

Questions to Ask a Provider

• Given my current metabolic profile (glucose, insulin, HbA1c), is MK-677 safe for me?
• What baseline labs should I obtain before starting?
• What dose should I start with, and should I titrate?
• How frequently should blood glucose and IGF-1 be monitored?
• How long should I use MK-677, and should I cycle it?
• Are there interactions with my current medications?
• What criteria would indicate I should discontinue?
• How does MK-677 compare to other options (injectable peptides, prescription GH) for my goals?

Sources & Further Reading

Core Clinical Trials

• Nass R, Pezzoli SS, Oliveri MC, et al. (2008) — "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial" — Annals of Internal Medicine
• Chapman IM, Bach MA, Van Cauter E, et al. (1996) — "Stimulation of the growth hormone (GH)–insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects" — Journal of Clinical Endocrinology & Metabolism
• Svensson J, Lönn L, Jansson JO, et al. (1998) — "Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure" — Journal of Clinical Endocrinology & Metabolism
• Murphy MG, Plunkett LM, Gertz BJ, et al. (1998) — "MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism" — Journal of Clinical Endocrinology & Metabolism

Bone Density

• Murphy MG, Weiss S, McClung M, et al. (2001) — "Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women" — Journal of Clinical Endocrinology & Metabolism

Pharmacology & Mechanism

• Patchett AA, Nargund RP, Tata JR, et al. (1995) — "Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue" — Proceedings of the National Academy of Sciences

Sleep

• Copinschi G, Van Onderbergen A, L'Hermite-Balériaux M, et al. (1997) — "Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men" — Journal of Clinical Endocrinology & Metabolism

Regulatory & Classification

• WADA: Prohibited List (current year)
• FDA: Bulk Drug Substances Used in Compounding

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.